Hexarelin

A potent GH secretagogue studied for cardiac and growth-hormone effects, with notable desensitisation on repeated dosing.

Hexarelin is classified as a ghrelin receptor agonist (gh secretagogue). Its current development status is: discontinued clinical development. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.

The Peptide Institute tracks Hexarelin because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.